When is ASBP's latest earnings report released?
The most recent financial report for Aspire biopharma holdings, inc. (ASBP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ASBP's short-term business performance and financial health. For the latest updates on ASBP's earnings releases, visit this page regularly.
What is the operating profit of ASBP?
According to the latest financial report, Aspire biopharma holdings, inc. (ASBP) reported an Operating Profit of -632.5K with an Operating Margin of -32,586.5% this period, representing a decline of 160.7% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ASBP's revenue growth?
In the latest financial report, Aspire biopharma holdings, inc. (ASBP) announced revenue of 1.94K, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does ASBP have?
At the end of the period, Aspire biopharma holdings, inc. (ASBP) held Total Cash and Cash Equivalents of 1.95M, accounting for 0.81 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ASBP go with three margins increasing?
In the latest report, Aspire biopharma holdings, inc. (ASBP) did not achieve the “three margins increasing” benchmark, with a gross margin of 45.5%%, operating margin of -32,586.5%%, and net margin of -95,337.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ASBP's profit trajectory and future growth potential.
What is the FCF of ASBP?
Aspire biopharma holdings, inc. (ASBP)'s Free Cash Flow (FCF) for the period is -1.1M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 152.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ASBP?
The latest valuation data shows Aspire biopharma holdings, inc. (ASBP) has a Price-To-Earnings (PE) ratio of -0.36 and a Price/Earnings-To-Growth (PEG) ratio of 0.2. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
